Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evolocumab and Alirocumab in healthy subjects
NCT04189484Phase 1Completed
- Sponsor
- Food and Drug Administration
- Start
- Jan 2020
- Primary completion
- Apr 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of evolocumab and alirocumab in hypercholesterolemia, sponsored by Food and Drug Administration. Started Jan 2020; status: completed.
02
Drugs
evolocumabalirocumab
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT04189484.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04189484.